Changes in expression of serum chemokine CXCL13 and IL-6 after hip replacement, and the relationship with lower limb vein thrombus

Guan,Zhiyu

doi:10.3892/etm.2019.8365

Changes in expression of serum chemokine CXCL13 and IL-6 after hip replacement, and the relationship with lower limb vein thrombus

Authors:
- Zhiyu Guan
View Affiliations

Affiliations: Department of Tramotology and Orthopedics, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550001, P.R. China
Published online on: December 20, 2019 https://doi.org/10.3892/etm.2019.8365
Pages: 2113-2118

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Changes in the expression of serum chemokine CXC ligand 13 (CXCL13) and interleukin-6 (IL-6), and the relationship with lower limb vein thrombus were explored. A total of 128 patients undergoing hip replacement in The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine from May 2017 to June 2019 were selected, and the patients suffering from lower limb vein thrombus were enrolled as group A and other patients not suffering from it were enrolled as group B. Enzyme‑linked immuno-sorbent assay was employed to determine the levels of serum chemokine CXCL13 and IL-6, and receiver operating characteristic curves of serum chemokine CXCL13 and IL-6 levels in diagnosing restenosis after surgery were drawn. Pearson's correlation coefficient was adopted to analyze the correlation between serum chemokine CXCL13 and IL-6, and the logistic regression analysis to analyze the risk factors affecting hip replacement in patients. The levels of serum CXCL13 and IL-6 in group A were significantly higher than those in group B (both P<0.001). The specificity and sensitivity of serum CXCL13 level in diagnosis of lower limb vein thrombus after hip replacement were 61.76 and 80.00%, respectively, and those of serum IL-6 level in diagnosis were 70.59 and 66.67%, respectively. Serum CXCL13 level was positively correlated with serum IL-6 level (P<0.001), and age, body mass index (BMI), CXCL13 level and IL-6 level of the patients were independent risk factors affecting the efficacy of hip replacement. Serum CXCL13 level and serum IL-6 level can be used as biological indexes for prediction of early lower limb vein thrombus after hip replacement, and logistic regression analysis revealed that the age of the patients, BMI, diabetes history, hyperlipidemia history, hypertension history, CXCL13 level and IL-6 level are independent risk factors affecting the efficacy of hip replacement.

View Figures

View References

1	Learmonth ID, Young C and Rorabeck C: The operation of the century: Total hip replacement. Lancet. 370:1508–1519. 2007. View Article : Google Scholar : PubMed/NCBI
2	Galia CR, Diesel CV, Guimarães MR and Ribeiro TA: Total hip arthroplasty: A still evolving technique. Rev Bras Ortop. 52:521–527. 2017. View Article : Google Scholar : PubMed/NCBI
3	Zagra L: Advances in hip arthroplasty surgery: What is justified? EFORT Open Rev. 2:171–178. 2017. View Article : Google Scholar : PubMed/NCBI
4	Pivec R, Johnson AJ, Mears SC and Mont MA: Hip arthroplasty. Lancet. 380:1768–1777. 2012. View Article : Google Scholar : PubMed/NCBI
5	Knight SR, Aujla R and Biswas SP: Total Hip Arthroplasty - over 100 years of operative history. Orthop Rev (Pavia). 3:e162011.doi: 10.4081/or.2011.e16. View Article : Google Scholar : PubMed/NCBI
6	Rogers BA, Garbedian S, Kuchinad RA, Backstein D, Safir O and Gross AE: Total hip arthroplasty for adult hip dysplasia. J Bone Joint Surg Am. 94:1809–1821. 2012. View Article : Google Scholar : PubMed/NCBI
7	Nam D, Nunley RM, Johnson SR, Keeney JA, Clohisy JC and Barrack RL: The effectiveness of a risk stratification protocol for thromboembolism prophylaxis after hip and knee arthroplasty. J Arthroplasty. 31:1299–1306. 2016. View Article : Google Scholar : PubMed/NCBI
8	Fukushima K, Takahira N, Uchiyama K, Moriya M, Minato T and Takaso M: The incidence of deep vein thrombosis (DVT) during hip arthroscopic surgery. Arch Orthop Trauma Surg. 136:1431–1435. 2016. View Article : Google Scholar : PubMed/NCBI
9	Han BK, Kuzin I, Gaughan JP, Olsen NJ and Bottaro A: Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: A pilot, prospective study. Arthritis Res Ther. 18:932016. View Article : Google Scholar : PubMed/NCBI
10	Allam SI, Sallam RA, Elghannam DM and El-Ghaweet AI: Clinical significance of serum B cell chemokine (CXCL13) in early rheumatoid arthritis patients. Egypt Rheumatol. 41:11–14. 2019. View Article : Google Scholar
11	Irani DN: Regulated production of CXCL13 within the central nervous system. J Clin Cell Immunol. 7:72016. View Article : Google Scholar
12	Sapan HB, Paturusi I, Jusuf I, Patellongi I, Massi MN, Pusponegoro AD, Arief SK, Labeda I, Islam AA, Rendy L, et al: Pattern of cytokine (IL-6 and IL-10) level as inflammation and anti-inflammation mediator of multiple organ dysfunction syndrome (MODS) in polytrauma. Int J Burns Trauma. 6:37–43. 2016.PubMed/NCBI
13	Rose-John S: The soluble interleukin 6 receptor: Advanced therapeutic options in inflammation. Clin Pharmacol Ther. 102:591–598. 2017. View Article : Google Scholar : PubMed/NCBI
14	Iba T and Levy JH: Inflammation and thrombosis: Roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost. 16:231–241. 2018. View Article : Google Scholar : PubMed/NCBI
15	Lankeit M and Held M: Incidence of venous thromboembolism in COPD: Linking inflammation and thrombosis? Eur Respir J. 47:369–373. 2016. View Article : Google Scholar : PubMed/NCBI
16	Wang J, Yang L, Li Q, Wu Z, Sun Y, Zou Q, Li X, Xu Z and Ye C: Construction of an adherence rating scale for exercise therapy for patients with knee osteoarthritis. BMC Musculoskelet Disord. 19:2632018. View Article : Google Scholar : PubMed/NCBI
17	Rahmati M, Nalesso G, Mobasheri A and Mozafari M: Aging and osteoarthritis: Central role of the extracellular matrix. Ageing Res Rev. 40:20–30. 2017. View Article : Google Scholar : PubMed/NCBI
18	Li YS, Xiao WF and Luo W: Cellular aging towards osteoarthritis. Mech Ageing Dev. 162:80–84. 2017. View Article : Google Scholar : PubMed/NCBI
19	Gademan MG, Hofstede SN, Vliet Vlieland TP, Nelissen RG and Marang-van de Mheen PJ: Indication criteria for total hip or knee arthroplasty in osteoarthritis: A state-of-the-science overview. BMC Musculoskelet Disord. 17:4632016. View Article : Google Scholar : PubMed/NCBI
20	Liu XW, Zi Y, Xiang LB and Wang Y: Total hip arthroplasty: A review of advances, advantages and limitations. Int J Clin Exp Med. 8:27–36. 2015.PubMed/NCBI
21	Burnett RSJ and Abos D: Total hip arthroplasty: Techniques and results. BC Med J. 52:455–464. 2010.
22	Jameson SS, Bottle A, Malviya A, Muller SD and Reed MR: The impact of national guidelines for the prophylaxis of venous thromboembolism on the complications of arthroplasty of the lower limb. J Bone Joint Surg Br. 92:123–129. 2010. View Article : Google Scholar : PubMed/NCBI
23	Shimoyama Y, Sawai T, Tatsumi S, Nakahira J, Oka M, Nakajima M, Jotoku T and Minami T: Perioperative risk factors for deep vein thrombosis after total hip arthroplasty or total knee arthroplasty. J Clin Anesth. 24:531–536. 2012. View Article : Google Scholar : PubMed/NCBI
24	Fisher WD: Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty. Can J Surg. 54:344–351. 2011. View Article : Google Scholar : PubMed/NCBI
25	Wang MF, Yang LH, Yang XL, Zhang RJ, Hou LH and Liu XE: Correlation of inflammatory marker and coagulation factors with deep vein thrombosis. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 18:753–756. 2010.(In Chinese). PubMed/NCBI